Suppression of Tumorigenicity 2 (ST2), a member of the interleukin-1 receptor (IL-1R) family, activates type 2 immune responses to pathogens and tissue damage via binding to IL-33. Dysregulated responses contribute to asthma, graft-versus-host and autoinflammatory diseases and disorders. To study ST2 structure for inhibitor development, we performed the principal component (PC) analysis on the crystal structures of IL1-1R1, IL1-1R2, ST2 and the refined ST2 ectodomain (ST2 ECD ) models, constructed from previously reported smallangle X-ray scattering data. 
Introduction
which prohibits follow-up investigation. While these data elucidate structural information of ST2, feasibility of binding between ST2 and small molecule ligands has not been explored. Recently, we reported that the flexible inter-domain motion in IL-1R type 1 (IL-1R1) ectodomain is mainly between the D2 and the D3 domain of IL-1R1 [24] . Our previous study implicated a full structural characterization of ST2 ECD ensemble conformations will be necessary to identify and assess potential small molecule binding sites of ST2 ECD .
In this work, we generated conformational ensemble of ST2 ECD using the efficient accelerated molecular dynamics (aMD) conformational sampling method starting with the welldefined IL-33-bound ST2 ECD structure. ST2 ECD conformations were analyzed based on principal component analysis (PCA) of the IL-1R1/2, ST2 crystal structures and the refined ligandfree ST2 ECD models using previously collected small-angle X-ray scattering (SAXS) data. Cluster analysis of the conformations was then carried out to select representative ST2 ECD models.
Comparison of the representative conformations with ST2/IL-33 and the experimental binding data both suggested that the D1-D2 domain of ST2 plays a dominant role to interact with IL-33. Computational binding site assessment of the representative conformations further determined locations in ST2 ECD that may interact with small molecules. Finally, we discussed the strategies to discover small molecule inhibitors targeting ST2 ECD .
Materials and Methods

Crystal structures used in this study
All protein structures labeled with PDBIDs were obtained from the Protein Data Bank [25] . They included the protein complex structures of ST2/IL-33 (PDBID: 4KC3 [21] ), IL-1R1/IL-1β (PDBID: 1ITB [26] ), IL-1R1/IL-1β/IL-1RAcP (PDBID: 4DEP [27] ), IL-1R1/IL-1Ra (PDBI-D:1IRA [28] ), IL-1R1/EBI-005 (PDBID: 4GAF [29] ), IL-1R1/AF10847 (PDBID: 1G0Y [30] ), and IL-1R2/IL-1β/IL-1RAcP (PDBID: 3O4O [31] ). Among them, EBI-005 is an IL-1β chimera and binds more potently to IL-1R1 than IL-1ß [29] . The ectodomains of IL-1R1/2 and ST2 were extracted from each structure for analysis. In the ST2 ectodomain structure, residues Q52-K55, E224-A231, Q272-N278 were unresolved. We modeled these missing segments using default parameters in the MOE [32] program. All proteins shown in the figures were prepared by UCSF Chimera program [33] .
Generation of ST2 ECD models using AllosMod-FoXS
The ST2 crystal structure corresponding to K19-N323 was used as the template structure to construct the SAXS derived ST2 ECD models. Missing residues in the crystal structure and the C-terminal Histag (six Histidine residues) were built using the MOE [32] program. All ST2 ECD models were generated by the AllosMod-FoXS web server [34] by fitting to the SAXS data. The most probable models setting was selected in the model calculations. Single state and ensemble models of up to 4 states determined by MultiFoXS and Minimal Ensemble Search (denoted as MES) algorithms were saved for analysis. The χ values of fitting to the SAXS profile in MultiFoXS were 1.96, 1.87, 1.78, 1.76 and those in MES were 1.58, 1.43, 1.43, 1.43 in the one-, two-, three-, and four-state models respectively.
MD simulation setup
ST2 ECD (sequence: K19-N323) from the crystal structure was used in the MD simulations.
Three N-Acetyl-D-Glucosamine bonded to N95, N140, N151 were removed whereas five pairs of cysteine residues forming disulfide bonds were bonded during simulations. To prepare protein structures for simulations, we have used the MOE program [32] to assign the protonation state of ionizable groups in ST2 ECD under the pH 7.4 physiological condition. The Amber 99SB
force field parameters [35] were used for the amino acids and the TIP3P [36] model for water molecules. The physiological salt concentration at 150 mM of NaCl was adopted in the simulation. The protein was embedded in an octahedron water box in which the distance between any protein atom to the edge of the box was set at 15 Å. The overall charge of the system was set neutral. The GPU modification to PMEMD [37] from Amber (version 12) [38] was used in all MD simulations. Preparation of the system for production run used the following procedures. A 3000-step minimization (steps 1-1000 using conjugated gradient followed by 2000 steps steepest decent) was first carried out. After minimization, a 50 ps constant volume and constant temperature (NVT) simulation was performed to raise the temperature of the system to 298K while constraining all heavy atoms with a 5 kcal/mol/Å 2 force constant with reference to the starting conformation. Using a 1 kcal/mol/Å 2 force constant to constrain all heavy atoms, the system underwent eight additional simulating annealing type of temperature changes under isobaric (P = 1 atm) conditions. The procedures included series of 50 ps runs by changing the temperatures from 298K to 350K, 350K to 400K, 400K to 450K, 450K to 500K, 500K to 550K respectively. Then, a 100 ps run was done at T = 550K followed by 50 ps runs with the temperature decreasing from 550K to 425K and 425K to 298K. Finally, a one ns pre-equilibration run with T = 298K without any constraint to protein atoms was performed in the isobaric isothermal environment (NPT, T = 298K and P = 1 atm) before the production run. The SHAKE [39] algorithm was used to fix bonds involving hydrogen atoms. The Particle mesh Ewald method [40] was used and the non-bonded cutoff distance was set at 10 Å. The time step was 2 fs, and neighboring pairs list was updated every 20 steps. For performing the accelerated MD (aMD) simulations, the first 2 ns production run based on the conventional MD (no modification of the potential energy function) was used to determine the average values of the potential energy for the total system (V total ) and the dihedral angle energy of the proteins (V dih ). The threshold potential energy was defined as V total + N atoms /5 (N atoms : total number of atoms in the system). Four threshold potential energies for the dihedral angle motion were used called AMD1, AMD2, AMD3 and AMD4 which were equal to Vdih + (number of residues) × 3.5, 4.2, 4.9, and 5.6 respectively. These parameters were taken as suggested by previous work [41] . A total simulation time of 120 ns was collected from 30 ns runs of aMD using AMD1-AMD4 parameters.
Principal component analysis and mean shift cluster analysis
The crystal structures of IL-1R1, IL-1R2, ST2 ectodomains used in the PCA were extracted from the complex structures of IL-1R1 with IL-1β (PDBID: 1ITB, chain B), IL-1Ra (PDBID: 1IRA, chain Y), AF10847 (PDBID: 1G0Y, chain R), EBI-005 (PDBID: 4GAF, chain B), IL-1β and IL-1RAcP (PDBID: 4DEP, chains B and E), IL-1R2 with IL-1β and L-1RAcP (PPDBID: 3O4O, chain C), and ST2 with IL-33 (PDBID: 4KC3, chain B). ST2 models included in the PCA were the 1-and 3-state models determined from the MultiFoXS and MES algorithms in this work. A total of 15 structures were analyzed using the PCA implemented in the Bio3D version 2.0 [42] . Detailed procedures of the PCA can be found at the Bio3D website (http:// thegrantlab.org/bio3d/) and our previous report [24] .
After the principal components (PCs) were determined, snapshots of ST2 ECD conformations obtained from aMD simulations were projected to the PC subspace. The coefficients of the first three components for each conformation were used to depict a point in the three dimensional PC subspace in all figures. Based on the PCA, we found the first seven principal components were sufficient to characterize 99% of structural variations in the 15 structures. The first seven PCs were then used in the mean shift cluster analysis provided in the ScikitLearn program [43] . Mean shift cluster analysis is a nonparametric clustering method [44] [45] [46] . Unlike k-mean clustering method, the mean shift clustering requires no prior knowledge of the number of clusters in the multidimensional data. The algorithm classifies data points by moving the data point via the density gradient defined by a kernel density estimator function with an assigned bandwidth until it reaches the maximum of a local density distribution called mode in pattern recognition. In our application here, each mode is the center of a cluster group. To perform the mean shift cluster analysis, snapshots of ST2 ECD conformations at every 10 ps from the aMD simulations were included. The quantile value was varied from 0.01 to 0.20 in the bandwidth estimation to analyze the stability of the numbers of cluster groups. Conformations closest to the centroid of each cluster group were selected to represent each cluster and denoted as representative conformations.
Sitemap analysis
We used Sitemap program [47] 
Protein expression and purification
Oligos for PCR construction were designed using Clone-manager (Scientific and Educational Software). IL-33 (residues 112-270) was cloned into an N-terminal His6-TEV expression vector, which was then transformed into Rosetta2™ (DE3) cells. Cultures were grown at 37°C to an OD 600 of 1.2 in Terrific Broth, induced with 0.4 mM IPTG and expressed overnight at 20°C. Cells were lysed by sonication in 10 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% β-mercaptoethanol with protease inhibitors and cellular debris pelleted by centrifugation. The resulting supernatant was incubated with Ni-NTA resin (Qiagen) equilibrated with 10 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM imidazole for 1 hr at 4°C and eluted with same buffer containing 300 mM imidazole. Tag removal occurred by dialyzing the eluate against 10 mM HEPES, pH 7.5, 150 mM NaCl and 1 mM DTT overnight at 4°C in the presence of TEV protease and incubating the protein with an additional Ni-NTA column. The flow through containing the protein was concentrated and loaded on to a Superdex 75 column (GE Heathcare) equilibrated with 10 mM HEPES, pH 7.5, 150 mM NaCl. The purified protein was stored at -80°C in the same buffer containing 10% glycerol.
ST2 constructs 19-206 and 19-323 were cloned into pH-HBM-7. This vector has a honeybee melittin signal sequence followed by a His tag and a TEV protease cleavage site [48] .
Expression trials indicated that High-five cells infected for 72 hours displayed the best yield of secreted protein. The conditioned media from two 1 L infection cultures for each construct was pooled for purification. All ST2 constructs were purified with the protocol described below. Media containing the expressed ST2 constructs were incubated with Ni-NTA resin (Roche) pre-washed with 10 mM HEPES, pH 7.2 and 150 mM NaCl (denoted Buffer A) for 4 hours at 4°C using a magnetic stirrer. Bound media was collected in a column and washed with Buffer A. The ST2 proteins eluted with Buffer A contained 300 mM imidazole and were dialyzed overnight at 4°C against Buffer A with TEV protease. The protein solution was then reapplied to a Ni-NTA column to remove the tag, then concentrated and applied to a Superdex 200 column (GE Healthcare) equilibrated with Buffer A.
For Bio-layer interferometry, the purified ST2 proteins and IL-33 were biotinylated by diluting the protein to 0.5 mg/mL in Buffer A, adding an equimolar ratio of Biotin-PEO4 linker (Pierce PN 21329) and incubating on ice for 2 hours. Unbound linker was removed via dialysis against 50mM sodium phosphate and 300 mM NaCl, pH 7.5.
Bio-layer Interferometry
BLI experiments were performed using an OctetRED96 instrument from ForteBio. All experiments were conducted at 25°C using 10 mM HEPES, pH 7.5, 150 mM NaCl, 0.005% Tween 20, 100 μM EDTA as the assay buffer. Assays were conducted in Greiner 96 well black flat-bottom microplates and were continuously shaken at 1000 RPM before measurements. Biotinylated ST2 was first loaded onto the Streptavidin (SA) sensors for 10 minutes at 20 μg/mL to achieve complete loading saturation. Complete loading reduced nonspecific binding which occurred on unloaded sensors. Serial dilutions of IL-33 were prepared on the Greiner plates. For ST2 ECD , new sensors were used for every IL-33 concentration due to slow dissociation. For ST2 D1-D2 , dissociation was complete in a short amount of time and sensors were reused between different IL-33 concentrations. In each sensorgram measurement, sensors loaded with ST2 were first equilibrated in the reference buffer for 10 minutes, then associated with IL-33 for 1 minute and dissociated for 1 minute for ST2 D1-D2 whereas the association and dissociation times for ST2 ECD were 15 minutes, and 15 minutes up to 2 hours, respectively. 50 μg/mL of biotinylated IL-33 was loaded onto sensors to serve as a negative-control parallel reference sensor. Raw kinetic data collected were processed using ForteBio data analysis software 7.1 and then analyzed in Prism 6.0 (GraphPad Software, La Jolla, California USA). Analysis of the data based on a 1:1 binding model gave k on and k off values which yielded the calculated K D values.
Results and Discussions
Refined models of ST2 ECD based on the SAXS data A ST2 homology model was used previously [21] to derive three structural models by fitting to the SAXS data of ST2 ECD employing the minimum ensemble search (MES) algorithm in BIL-BOMD [49] . Examination of these models showed that a flexible loop (Q272 to N278, unresolved in the ST2/IL-33 crystal structure) penetrated into the D3 domain. Further, the distances between C238 and C282 in all three models were 21 Å which are incompatible with a disulfide bond distance observed in the crystal structure. The large distance separation between C238 and C282 originated from the ST2 homology model template and the lack of distance constraint between C238 and C282 in the model construction.
Here, we used the well-resolved ST2 ECD template structure extracted from the ST2 ECD /IL-33 crystal structure and the web-based program, AllosMod-FoXS [34] Most models also showed reasonably close distances between matching pairs of 10 cysteine residues forming disulfide bonds. Exceptions were found in three models (9pm31, 3pm68, 5pm93) in which distances between C111 and C151 were 8.1, 8.1 and 11.2 Å. C111 and C151 are both in loop regions and have largest solvent accessible surface areas than the other eight cysteine residues according to the ST2 crystal structure. The bonding between C111 and C151 is expected to constrain the D1 and D2 domains in the dynamical motion of ST2 but not the overall backbone conformation of the three models. Alignment of these models with the ST2 crystal structure (Fig 1B) demonstrated that the flexibility of ST2 ECD observed in solution can be attributed to the orientational motion of the D3 domain with respect to the D1-D2 domain mediated by a loop (sequence: K203-S209) between the D2 and D3 domains similar to the IL-1R1 ectodomain [24] . Most models also resemble three previous models [21] except 7p22 and 7p26 in which the D3 domain swings further away from the D1-D2 domain.
Characterization of ST2 ECD conformations based on the principal component analysis
Previous studies have shown PCA as an informative tool to characterize protein conformational changes by analyzing experimental structures [51] and conformations obtained from MD simulations [52] . To analyze the ST2 ECD conformations and their changes in the MD simulations, we performed the principal component analysis (PCA) [53] by combining crystal structures and the SAXS derived models. Only one ST2 ECD /IL-33 structure (PDBID: 4KC3) is currently available; however, IL-1R1, IL-1R2 and ST2 are in the same IL-1R family. The sequence identities of the ectodomains between ST2 and IL-1R1/2 are 18% and all contain the D1-D3 domains. The crystal structures of IL-1R1, IL-1R2, ST2 included in the PCA were described in the Materials and Methods. Although SAXS derived models cannot provide accurate atomic details of the ST2 ECD conformations, the PCA requires only the Calpha positions of the proteins which are characterized by the folds and shapes of the SAXS models [54] . Therefore, we included the SAXS derived models to supplement limited crystal structures, and to provide the ligand-free ST2 away from both ST2 and IL-1R1 along the PC2 degree of freedom. Our structural alignment indicated the D3 domain of IL-1R2 deviates more from that of IL-1R1. It is unclear whether the difference is associated with the IL-1RAcP binding because no other IL-1R2 structure is available. For the AF10847-bound IL-1R1 conformation (PDBID: 1G0Y), the D1 and D3 domains make close contact and its conformation was mapped to another location involving changes in PC1 and PC2 degrees of freedom.
The conformations and the projected locations of SAXS models determined by MultiFoXS and MES are shown in Fig 2B and 2C . Their locations differ from the known crystal structures and cover a wider range of PC subspaces. Based on the proximity in location, we identified similar conformations in 7p22/7p26, 3p74/3p68 and 5p93/5p96. Although three previous models were not included in the PCA, projection of their conformations to the PC subspace (green circles) indicated that SM1 and SM2 are close to 5p93 and 3p74. This suggests that SM1 and SM2 captured major conformational shapes because 5p93 and 3p74 have the largest weights in the 3-state models. We next projected the ST2 ECD conformations collected from 22 ns of MD simulation to the PC subspace in Fig 2D ( Conformational sampling of ST2 ECD using the accelerated MD method Fig 2D demonstrated an example of limited conformational sampling using conventional MD simulations. To overcome local conformational sampling and access higher energy states compatible with ligand binding [55] , we performed the accelerated MD (aMD) sampling [41] starting with the IL-33 bound ST2 ECD crystal structure. We have previously shown that aMD allows more efficient conformational sampling of IL-1R1 ectodomain than the conventional MD simulations for the same length of simulation time [24] . This was attributed to the adjustment of the potential energy function which allows the protein to cross energy barriers during simulations. Here, we used four sets of parameters in the aMD simulations, denoted by AMD1-4, to progressively produce shallower energy wells and access conformations separated by higher energy barriers in the energy landscape. Fig 3A shows that the AMD1 parameters allowed efficient and diverse conformational sampling when compared with those obtained from conventional MD simulations (cf. Fig 2D) . Although parameters based on AMD2-4 provided conformational sampling of ST2 ECD in different PC subspaces, yet they are more localized. Combining ST2 ECD conformations from all 4 sets of parameters indicated that they provide broad coverage of PC subspace guided by the locations of the crystal structures and the SAXS-derived models. While the crystal structures cover some of the ligand-bound conformations, the SAXS-derived models represent the ligand-free ST2 ECD conformations in solution.
Each aMD simulation was extended by another 10 ns to determine the convergence of the sampling. Projections of the conformations from the extended simulations, shown in Fig 4A, indicated that the sampling using the AMD1 parameters remains diverse in the PC subspace while the conformations sampled using the AMD2-4 parameters were trapped to three separate localized regions. This suggested that conformations collected from a total of 80 ns simulations using AMD1-4 parameters covered the majority of the PC subspace and the extended 40 ns simulations gave only minor additional coverage of the PC subspace. To visualize the diverse ST2 ECD conformations obtained from the aMD sampling, we performed the mean shift cluster analysis to group similar conformations in the PC subspace into the same cluster. Each cluster group in the conformational ensemble of ST2 ECD is represented by the conformations corresponding to the centroid of the cluster. In the mean shift cluster analysis, the number of data points and the quantile value in the bandwidth estimation can dictate the number of cluster groups. To assess the effects of both parameters on the number of cluster groups, we included 4000 and 6000 conformations taken from a total of 80 and 120 ns of aMD simulations and varied the quantile value from 0.2 to 0.01. The results shown in Fig 4B indicated that setting the quantile value between 0.12 and 0.06 leads to relatively stable number of clusters reflecting the stability of data classification in the cluster analysis [44] . When the quantile value is lower than 0.04, the number of clusters starts to increase substantially. The number of conformations included in the analysis (80 ns versus 120 ns) made small differences to the number of clusters determined. We further compared the centroids of the clusters between 80 and 120 ns using the quantile value = 0.07 and 0.06 in Fig 4C-4F . In Fig 4C and 4E , locations of cluster 2, 3, 5, 6, and 7 were not changed between the two quantile values. Similar trend was found in Fig 4D and 4F . When the quantile value is 0.06, we found higher resolution of clusters in the regions covered by clusters 1, 2, 3 5 and 6 in Fig 4C or clusters 1, 4 and 5 in Fig 4D. The change of the M2 location and emergence of M8 between Fig 4F and 4E can be attributed to increased conformational populations in the PC subspaces from the extended sampling simulations as shown in Fig 4A. Comparison between Fig 4E and 4F indicated variations in the locations of N8, N9, M2, and M8 but not other cluster groups. This reflects that increased population of certain localized states in the extended aMD simulations may bias the mean shift cluster analysis to select these stationary states. To retain the diversity of representative conformations, we included N1-N9 and M1-M8 in the subsequent analysis.
To determine the relation between these representative conformations with the SAXS models, we calculated the Euclidean distances between them as listed in Table 1 . Because these conformations are projected to the PC subspace, the Euclidean distance is not directly related to distance in angstrom for interpretation. However, if we use the distance of less than 100 a.u. in Table 1 to infer the closeness between conformations, we found that 9 of 17 representation conformations are close to some of the SAXS derived models (shown in bold italic fonts in Table 1 ) are attributed to the twisted D3 domain relative to the D1-D2 domain. A small twisted angle between domains tends to give a larger RMSD value. Furthermore, aMD sampled additional conformational spaces presumably lower populated ST2 conformations not characterized by either the crystal structures or SAXS derived models. domain. Three conformations (M1, M2, M8) corresponding to the trapped regions in the extended simulations from 80 to 120 ns (Fig 4A) are also provided. Of note, the D3 domain in N1 and M2 are in opposite orientation relative to the D1-D2 domain. Although N8, N9 and M8 are close to each other in the PC subspace, the D3 domain exhibits substantial differences in orientation. This partly reflects the ruggedness of the energy landscape in this location of the PC subspace. determined by the isothermal titration calorimetry assay [23] and the Biacore assay [21, 23] . Table 1 . Euclidean distances between N1-N9, M1-M8 and the SAXS derived model conformations in the PC subspace. The distance in PCA subspace is calculated using the coefficients of the PC vectors of each conformation projected to the PC subspace and is in arbitrary units (a.u.). RMSD calculations are based on the Cα, C and N atoms of the protein backbone. The states shown in bold italic font are close to nearby SAXS derived models with distances of less than 100. Based on our data, the D1-D2 domain of ST2 ECD contributed 83% to the binding free energy between ST2 ECD and IL-33. We also observed 6 versus 186 fold differences in k on and k off rate Binding sites analysis of the representative conformations of ST2
ECD using Sitemap
Structures of the representative conformations permit identification and assessment of small molecule binding sites in ST2 ECD . For this analysis, we used the Sitemap [56] program. Sitemap has been used to identify potential allosteric modulator sites in IL-1R1 in our previously report [24] , in the druggability analysis of Bromodomain proteins [57] , and in the protein-protein interaction sites evaluation [58] . Here, we examined two indexes from the Sitemap analysis, i.e. Dscore (defined below) and the volume of the binding sites (Site Volume) as shown in Fig 7A. The Dscore value is an overall assessment of the likelihood that the identified binding site can interact with small molecules. Previous evaluation of Sitemap on a set of co-crystal structures with known inhibitor affinities suggested that a binding site assessed with a Dscore ! 0.83 is "druggable" [56] . Although this measure does not account for the adaptability of the binding site to ligand binding, it prioritizes binding sites for follow-up investigation. Using this value, we found that 15 of 41 sites in N1-N9 and 18 of 34 sites in M1-M8 were classified as druggable sites (see Fig 7A) corresponding to 37% and 53% of all detected sites respectively. Greater than 50% of these druggable sites have site volumes less than 300 Å
3
. Nine druggable sites have volumes between 400 and 550 Å 3 . Three druggable sites detected in M2 have much higher Dscore values and larger site volumes. This is attributed to that M2 adopts a conformation similar to the AF10847-bound IL-1R1 structure in which D3 is in close contact with D1. Because N1-N9 and M1-M8 are representative ST2 ECD conformations from the conformations obtained from the aMD simulations, we expect that at least a third of detected small molecule binding sites are druggable in the conformational ensemble of ST2 ECD .
Analysis of the druggable binding sites revealed two common locations in ST2 ECD . Majority of the druggable sites are located at the interface between the D1 and D2 domains for all conformations analyzed as shown in Fig 7A. Two conformations, N5 and N7, in which the D3 domain adopted a stretched orientation revealed a potential druggable site at the interface between the D2 and D3 domains (Fig 7B) . Besides the two common locations, the D1 domain is close to the D3 domain in N8 and formed a binding site suitable for small molecule binding (green envelop shape in Fig 7B) . Conformation of N8 is similar to the AF10847-bound IL-1R1 structure and the location of the druggable site between the D1 and D3 domains in N8 resembles that identified in IL-1R1 [24] . Whether antagonistic peptides analogous to AF10847 or small molecules can be found to bind with ST2 ECD adopting the N8 conformation remains to be determined. Among these druggable sites, the sites at the interface between the D1 and D2 domains frequently gave the highest Dscore value and were also larger in size. The shape of the sites at the interface between the D2 and D3 domains however show greater variability and are dictated by the relative orientation between the D2 and D3 domains. 
Conclusion
Small-angle X-ray scattering has been widely used to investigate protein conformations in solution [59, 60] . Structural models constructed by fitting to the SAXS data gave additional information of the protein conformations in solution to corroborate with crystal structures or NMR data. They can be particularly valuable to provide architectures of protein conformations in solution when NMR structures are unavailable for large proteins or protein complexes. In this study, we incorporated the backbone conformations from the SAXS-derived models (ligandfree) with crystal structures (ligand-bound) in the PCA to construct the conformational space of ST2 ECD for analyzing the conformations obtained from MD simulations. ECD crystal structure) respectively. Druggable sites detected at the interface between the D1 and D2 domains are shown as surface shapes. The upper structure shows the druggable sites found in N1-N9 using the IL-33 bound ST2 structure as a reference, and the lower one shows those found in M1-M8 where all conformations were aligned. (B) Locations of druggable sites at the D2-D3 interface identified in N5 and N7 are colored as blue and pink. A unique site (green) between the D1 and D3 domains found in N8 is shown and compared with the AF10847-bound IL-1R1 crystal structure. and IL-1Ra are 7 μM, > 10 μM and 28 nM respectively [28] whereas the K D of the D1-D3 domain of IL-1R1 with IL-1β is 2 nM [29] . IL-1Ra was further shown to interact primarily with the D1-D2 domain of IL-1R1 in a crystal structure [28] . The D1-D2 domain of IL-1R1 contributed only 58% in binding free energy with its endogenous activating cytokine IL-1β much less than that between ST2 ECD and IL-33. This cannot be attributed to the inability of the D1-D2 domain of IL-1R1 to potently bind with cytokines as it binds with antagonistic IL-1Ra using primarily the D1-D2 domain at a K D of 28 nM. There appears to be functional differences in the cytokine signaling and regulation between IL-1R1/IL-1β and ST2/IL-33. Our hypothesis of recognition between ST2 ECD and IL-33 does not preclude that the membrane-bound ST2 binds to IL-33 using a different mechanism. The D3 domain of the membrane-bound ST2 is restrained at the cell membrane and can potentially modulate inter-domain motion between the D2 and D3 domains. Differences in the IL-33 recognition between membrane-bound ST2 and ST2 ECD remain to be determined.
Our binding site identification and assessment determined two major locations in ST2
ECD that are suitable for small molecule binding. Druggability evaluation informed that a third of all detected binding sites in the representative conformations have Dscore values ! 0.83 implying druggability. The primary and most frequently detected location (Site 1) is at the interface between the D1 and D2 domains whereas the second location (Site 2) is between the D2 and D3 domains. Site 1 yields a higher Dscore value and adopts a relatively rigid conformation as observed in simulations. Our binding data also show that the D1-D2 domain of ST2 ECD interacts with IL-33 potently. Compounds bound to this site can impact the inter-domain motion between D1 and D2 and interfere directly with IL-33 binding. Thus, Site 1 is an attractive location to seek small molecule inhibitors with high potencies. Higher variability in the binding site conformations was found at Site 2 because it engages the flexible D3 domain. Ligands bound to Site 2 can potentially trap the orientation of the D3 domain and cause ineffective binding between ST2 ECD and IL-33 similar to the strategy suggested in our study of IL-1R1 [24] .
Another unique site was found in N8 when the D1 and D3 domains make close contacts. Small molecules binding to this site in N8 can potentially stabilize N8 similar to the antagonistic action of the AF10847 peptide imposed on IL-1R1 [30, 61] . Given the interest to selectively inhibit sST2 or membrane-bound ST2 to attenuate T H 2 response, binding sites besides Site 1 need to be explored. Although we only showed representative conformations from the cluster groups in this work, other conformations in each cluster group can be exploited in in silico hit discovery. Computational simulations have been instrumental to facilitate the discovery of transient and cryptic pockets in proteins permissible for ligand binding in mutant p53 [62] , TEM-1 β-latamase [63] , IL-2, Rnase H [64] and Bcl-xL [65] employing different approaches. These transient protein conformations are difficult to identify by experimental means alone. In this work, we reported another example of discovering potential small molecule binding sites in ST2 exhibiting large interdomain motion. Follow-up studies will be reported in due course. ST2/IL-33 signaling is involved with various T-cell mediated immune responses and promotes the production of the T H 2 associated cytokines. The ST2/IL-33 axis has been associated with pathological diseases including asthma, rheumatoid arthritis, atherosclerosis and GVHD [9, 13, 15, 66] . Therapeutic interventions in the ST2/IL-33 axis will provide novel treatment options to these immunity-related diseases or disorders. Although antibodies are widely used to block the extensive interactions between cytokine receptors and cytokines [67] , small molecule inhibitors/modulators targeting membrane-bound receptors including TLR-8 [68] and FGFR [69] have been reported. In summary, our study characterized ST2 ECD conformations
and assessed their small molecule binding sites that can be useful to discover small molecules targeting ST2 ECD . The approach could potentially be applied to other cytokine receptors exhibiting similar domain architectures and inter-domain flexibility.
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